Yvonne McGrath - Jun 1, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
VP, Research and Development
Signature
/s/ Michel Detheux, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Jun 1, 2021
Transactions value $
-$126,371
Form type
4
Date filed
6/3/2021, 04:17 PM
Previous filing
Jun 3, 2021
Next filing
Jun 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $32.2K +7.6K $4.23 7.6K Jun 1, 2021 Direct
transaction ITOS Common Stock Sale -$153K -7.6K -100% $20.18 0 Jun 1, 2021 Direct F1, F2
transaction ITOS Common Stock Options Exercise $1.37K +323 $4.23 323 Jun 2, 2021 Direct
transaction ITOS Common Stock Sale -$6.46K -323 -100% $20.00 0 Jun 2, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -7.6K -6.85% $0.00 103K Jun 1, 2021 Common Stock 7.6K $4.23 Direct F3
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -323 -0.31% $0.00 103K Jun 2, 2021 Common Stock 323 $4.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.95, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 One-fourth of the shares subject to the stock option vest on the one-year anniversary of the vesting commencement date, subject to the reporting persons continuous service relationship with the Issuer through such date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting persons continuous service relationship with the Issuer through each applicable vesting date.